CompletedNCT07193901
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicide prevention or Behavior
Medication studyAges 18–64China
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Beijin and 14 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: May 27, 2025
- Recruitment status
- Completed
- Enrollment listed in the registry
- 98
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- China
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT07193901
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled Phase Il Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Beijin · Beijing · Changsha
9 more locations
- Chengdu
- Hangzhou
- Hefei
- Luzhou
- Nanchang
- Ningbo
- Suzhou
- Wuxi
- Zhumadian
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Sichuan Purity Pharmaceutical Technology Co., Ltd., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Low Dose PRT042 nasal spray, median Dose PRT042 nasal spray, high dose PRT042 nasal spray and placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
